Medical Condition News

RSS

Combination of other opioids with methadone therapy can lead to overdose or fatal consequences

A new study has shown harmful prescription patterns of powerful painkillers among a substantial number of Ontario patients who received methadone therapy to treat their opioid addiction.

29 Nov 2011

Beta blockers prevent negative effects of stress

Stressed people fall into habits and their behaviour is not goal-directed. That the neurotransmitter norepinephrine plays a decisive role here is now reported in the Journal of Neuroscience by scientists from Bochum led by Dr. Lars Schwabe (RUB Faculty of Psychology).

29 Nov 2011

New way of monitoring blood pressure wins innovation and technology award

Revolutionary device developed by University of Leicester, in collaboration with biotech SME HealthStats in Singapore and the NHS, wins Times Higher Education Award.

29 Nov 2011

CINJ experts available to discuss cancer-related fatigue

Between 70 and 100 percent of cancer patients receiving treatment suffer from fatigue related to their condition, according to the American Cancer Society, and up to one-half of all survivors have reported fatigue lasting months or even years after treatment. Fatigue can be one of the most distressing side effects of cancer treatment and can sometimes be overlooked by patients, caregivers and doctors.

28 Nov 2011

Treatment for acute urinary retention due to BPH varies among countries

Men who experience a sudden inability to pass urine because of a non-cancerous enlarged prostate are hospitalised and treated differently depending on where they live, according to an international study published online by the urology journal BJUI.

28 Nov 2011

FDA approves Mylan's generic Dexrazoxane for Injection ANDA

Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dexrazoxane for Injection, packaged in 250 mg and 500 mg Single-use Vials. This product is the generic version of Pharmacia & Upjohn's Zinecard® for Injection, a chemoprotective agent.

28 Nov 2011

FDA grants IND for AEZS-130 Phase 2A trial in cancer cachexia

Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has granted Jose M. Garcia, MD, PhD, Assistant Professor, Division of Diabetes Endocrinology and Metabolism, Departments of Medicine and Molecular and Cell Biology, Baylor College of Medicine and Michael I. DeBakey Veterans Administration Medical Center, in Houston Texas, an Investigational New Drug approval for the initiation of a Phase 2A trial to assess the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130, in patients with cancer cachexia.

28 Nov 2011

Enrollment complete in SUSTAIN Phase 2b clinical trial for atherosclerotic CVD

Resverlogix Corp. today announced that SUSTAIN, a Phase 2b clinical trial comprised of 176 subjects, is fully enrolled.

28 Nov 2011

European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved ONGLYZA (saxagliptin) for use as a combination therapy with insulin (with or without metformin) to improve blood sugar (glycaemic) control in adult patients with type 2 diabetes.

28 Nov 2011

Leica Microsystems announces availability of ChromoPlex 1 Dual Detection for BOND

Leica Microsystems announced today the availability of Leica ChromoPlex 1 Dual Detection for BOND, the first fully automated one-step detection system allowing the co-visualization of mouse and rabbit antibodies on a single slide.

28 Nov 2011

IsoRay initiates shipment of GliaSite radiation therapy system

IsoRay, Inc. announced today it has shipped its first GliaSite radiation therapy system. The Company initiated sales after receiving final approval this week from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system.

28 Nov 2011

Inspiration commences enrollment in second OBI-1 Accur8 clinical trial program for congenital hemophilia A

Inspiration Biopharmaceuticals, Inc. today announced the initiation of patient enrollment in the second of two pivotal studies in the Company's OBI-1 Accur8 clinical trial program.

28 Nov 2011

FDA grants Perrigo final approval for Guaifenesin Extended-Release Tablets ANDA

Perrigo Company today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg.

28 Nov 2011

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that they have initiated a Phase 3 clinical trial evaluating the efficacy and safety of EYLEA (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

28 Nov 2011

Henry Schein launches new integrated comprehensive solution to treat sleep apnea

Henry Schein, Inc., the largest provider of health care products and services to office-based practitioners, today announced the launch of its Sleep Complete™ program, a new integrated comprehensive solution that provides all of the information and products necessary for the successful implementation of dental sleep medicine into the dental practice.

28 Nov 2011

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Micromet, Inc. today announced that it has initiated a phase 2 trial of its lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

28 Nov 2011

Exelixis and NCI's CTEP enter CRADA to further evaluate cabozantinib

Exelixis, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) for further evaluation of cabozantinib, Exelixis' lead compound, in a variety of solid tumors.

28 Nov 2011